Radiation therapy can cause significant toxicity in patients. Lower doses help limit this damage, but can also decrease the treatment’s effectiveness. Dr. Olcina is exploring how we might address these toxicities without compromising the treatment itself. Radiotherapy works in part by stimulating an adaptive immune response against cancer, which benefits patients. But it may also activate an innate immune response through the complement pathway that can promote tissue-damaging inflammation. To determine how we might prevent this, she’s characterizing how different doses of radiation activate the complement pathway and how it affects other immune cells, with the goal of identifying ways that immunotherapy might be able to boost radiotherapy’s benefits while reducing its drawbacks.
Stanford University | Bladder Cancer, Colorectal Cancer, Esophageal Cancer | 2016 | Amato J. Giaccia, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI Fellow Dr. Tim Fessenden of MIT shared his day with the CRI social community on Friday, June 26.
CRI hosted esteemed immunologists Carl June, Miriam Merad, and E. John Wherry to highlight immunotherapy’s pivotal role in addressing the COVID-19 pandemic.